Sodium-Glucose Co-transporter 2 Inhibitors in the Failing Heart: a Growing Potential

Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are a new drug class designed to treat patients with type 2 diabetes (T2D). However, cardiovascular outcome trials showed that SGLT2i also offer protection against heart failure (HF)–related events and cardiovascular mortality. These benefits appea...

Descripción completa

Detalles Bibliográficos
Autores principales: Brito, Dulce, Bettencourt, Paulo, Carvalho, Davide, Ferreira, Jorge, Fontes-Carvalho, Ricardo, Franco, Fátima, Moura, Brenda, Silva-Cardoso, José Carlos, de Melo, Rachel Tavares, Fonseca, Cândida
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7242490/
https://www.ncbi.nlm.nih.gov/pubmed/32350793
http://dx.doi.org/10.1007/s10557-020-06973-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7242490/
https://www.ncbi.nlm.nih.gov/pubmed/32350793
http://dx.doi.org/10.1007/s10557-020-06973-3

Ejemplares similares